YP2 Stock Chart & Stats
€2.30
€0.00(0.00%)
At close: 4:00 PM EDT
€2.30
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.66 - €3.54
Previous CloseN/A
Volume0.00
Average Volume (3M)106.00
Market Cap
€10.44M
Enterprise Value€11.57M
Total Cash (Recent Filing)€13.08M
Total Debt (Recent Filing)€7.94M
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
Nov 18, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding4,978,216
10 Day Avg. Volume70
30 Day Avg. Volume106
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.16Price Target Upside906.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)€1.69M
Bulls Say, Bears Say
Bulls Say
GLIX1 Clinical AdvancementGLIX1 has moved into human testing with enrollment tracking to plan and early safety and tolerability described positively. This clinical execution creates a credible pathway to future efficacy data and broadens BioLineRx’s oncology pipeline beyond its marketed product.
Moderate LeverageModerate and improving leverage provides more financial flexibility than a heavily indebted biotech balance sheet would. Lower debt can reduce financing pressure and preserve room for research, clinical development and commercialization, although continuing losses still limit this advantage.
Commercialized APHEXDA Revenue StreamAPHEXDA is an approved product already generating royalty income, giving BioLineRx a commercial foothold while its pipeline advances. Continued adoption could provide a recurring funding source and validate the company’s partnering and commercialization model over the next several quarters.
Bears Say
Deep Operating LossesGross profitability is insufficient to cover operating expenses, leaving BioLineRx deeply loss-making despite revenue from its product and partners. Persistent operating losses weaken internal funding capacity and make future earnings dependent on stronger product adoption or successful pipeline development.
Persistent Cash BurnThe company is not currently self-funding operations, as substantial cash consumption continues alongside clinical and commercialization spending. Ongoing negative cash flow can constrain development choices and increase reliance on financing, royalties or milestones to sustain the operating plan.
APHEXDA Adoption HurdlesAPHEXDA’s commercial opportunity may take time to scale because treatment-center practices must change and generic alternatives were already available. Slower adoption would limit royalty growth, prolong dependence on external funding and reduce the product’s ability to offset pipeline costs.
Bioline RX Ltd Sponsored ADR News
YP2 FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was €1.66 and its highest was €3.54 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is €10.44M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is Nov 18, 2026 which is in 39 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Aug 31, 2026. The company reported €0 earnings per share for the quarter.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -0.34.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,978,216 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went up 7.477%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in DE:YP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
YP2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive, driven by strong GLIX1 clinical enrollment and early safety and tolerability, encouraging glioblastoma and ovarian-cancer preclinical results, continued PDAC trial enrollment, APHEXDA royalty generation, and a cash runway extending into the first half of 2027. Offsetting points included a higher quarterly net loss, flat revenue, uncertainty around the evolving PDAC treatment landscape, and the substantial work still required to expand APHEXDA adoption.View all DE:YP2 earnings summariesYP2 Stock 12 Month Forecast
Average Price Target
€23.16
▲(906.88% Upside)